secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2026-05-13T12:05:18+00:00
Accession:  0001683168-26-003766
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences Q1 2026 net loss down 49% to $0.5M; royalty revenue up 36% to $0.8M
--------------------------------------------------------------------------------

- Net loss of $0.5M ($0.04 per share) vs $0.9M a year ago; cash $7.3M at March 31, 2026.
- Royalty revenue $0.8M (+36% YoY) primarily from Takeda sublicense agreement.
- R&D expenses $0.7M (-25% YoY) due to lower preclinical costs; G&A $0.6M, flat.
- DNase I platform progress: translational data, manufacturing readiness, Israeli Ministry of Health approval for CAR T study.
- Company continuing evaluation of strategic alternatives to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316826003766/0001683168-26-003766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316826003766/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-003766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer